62 related articles for article (PubMed ID: 9768823)
1. Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer.
Chow EJ; Aggarwal S; Doody DR; Aplenc R; Armenian SH; Baker KS; Bhatia S; Blythe N; Colan SD; Constine LS; Freyer DR; Kopp LM; Laverdière C; Leisenring WM; Sasaki N; Vrooman LM; Asselin BL; Schwartz CL; Lipshultz SE
J Clin Oncol; 2023 Apr; 41(12):2248-2257. PubMed ID: 36669148
[TBL] [Abstract][Full Text] [Related]
2. Comparison of bolus administration and short-term infusion versus long-term infusion of doxorubicin in terms of cardiotoxicity and efficacy.
Ghiami H; Omidkhoda N; Seddigh-Shamsi M; Rahimi H; Arasteh O
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):3771-3780. PubMed ID: 38095650
[TBL] [Abstract][Full Text] [Related]
3. Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin.
Li J; Chang HM; Banchs J; Araujo DM; Hassan SA; Wagar EA; Yeh ETH; Meng QH
Cardiooncology; 2020; 6():1. PubMed ID: 32154027
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.
Asselin BL; Devidas M; Chen L; Franco VI; Pullen J; Borowitz MJ; Hutchison RE; Ravindranath Y; Armenian SH; Camitta BM; Lipshultz SE
J Clin Oncol; 2016 Mar; 34(8):854-62. PubMed ID: 26700126
[TBL] [Abstract][Full Text] [Related]
5. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients.
Seif AE; Walker DM; Li Y; Huang YS; Kavcic M; Torp K; Bagatell R; Fisher BT; Aplenc R
Pediatr Blood Cancer; 2015 Apr; 62(4):704-9. PubMed ID: 24668949
[TBL] [Abstract][Full Text] [Related]
6. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.
Khouri MG; Douglas PS; Mackey JR; Martin M; Scott JM; Scherrer-Crosbie M; Jones LW
Circulation; 2012 Dec; 126(23):2749-63. PubMed ID: 23212997
[No Abstract] [Full Text] [Related]
7. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know.
Ewer MS; Ewer SM
Nat Rev Cardiol; 2010 Oct; 7(10):564-75. PubMed ID: 20842180
[TBL] [Abstract][Full Text] [Related]
8. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients.
Nousiainen T; Jantunen E; Vanninen E; Hartikainen J
Br J Cancer; 2002 Jun; 86(11):1697-700. PubMed ID: 12087452
[TBL] [Abstract][Full Text] [Related]
9. Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers.
Sparano JA; Brown DL; Wolff AC
Drug Saf; 2002; 25(5):301-11. PubMed ID: 12020170
[TBL] [Abstract][Full Text] [Related]
10. Cardiac Neoplasms.
Rosenberg FM; Chan A; Lichtenstein SV; McManus BM
Curr Treat Options Cardiovasc Med; 1999 Oct; 1(3):243-252. PubMed ID: 11096489
[TBL] [Abstract][Full Text] [Related]
11. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
Lopez M; Vici P
Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
[TBL] [Abstract][Full Text] [Related]
12. Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation.
Tonkin K; Bates M; Lieu D; Arundell E; Williamson T; Zagari M
Can J Oncol; 1996 Nov; 6(2):458-73. PubMed ID: 12056098
[TBL] [Abstract][Full Text] [Related]
13. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
[TBL] [Abstract][Full Text] [Related]
14. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
Sparano JA
Semin Oncol; 1998 Aug; 25(4 Suppl 10):66-71. PubMed ID: 9768827
[TBL] [Abstract][Full Text] [Related]
15. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
Swain SM
Semin Oncol; 1998 Aug; 25(4 Suppl 10):43-7. PubMed ID: 9768823
[TBL] [Abstract][Full Text] [Related]
16. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
